Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.38 |
| ▸ | ACE | P12821 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6578880 | 0.80 | MMP2 (0.56) | MMP2MMP9CA1CA2FOLH1 | |
| SCHEMBL6578877 | 0.80 | MMP2 (0.56) | MMP2MMP9CA1CA2FOLH1 | |
| SCHEMBL7543508 | 0.79 | MMP2 (0.47) | MMP2MMP9CA1CA2HPGDS | |
| SCHEMBL7543514 | 0.79 | MMP2 (0.47) | MMP2MMP9CA1CA2HPGDS | |
| SCHEMBL2982685 | 0.77 | MMP2 (0.45) | MMP2MMP9CA1CA2HPGDS | |
| SCHEMBL2982680 | 0.77 | MMP2 (0.45) | MMP2MMP9CA1CA2HPGDS | |
| SCHEMBL8209818 | 0.77 | CA1 (0.48) | MMP2MMP9CA1CA2HPGDS | |
| SCHEMBL8209820 | 0.77 | CA1 (0.48) | MMP2MMP9CA1CA2HPGDS | |
| SCHEMBL29022050 | 0.75 | TLR2 (0.49) | MMP2MMP9CA1CA2FOLH1 | |
| SCHEMBL29022047 | 0.75 | ALOX5 (0.50) | MMP2MMP9CA1CA2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777073-B2 | Topical delivery system for antiaging and skin whitening agents | BIODERM RESEARCH (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | BIODERM RESEARCH (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | TYR, MMP17, MMP1 | MMP2 75/4885MMP9 64/4885CA1 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.